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Patients cared for in the intensive care unit (ICU) undergo
multiple interventions to treat serious medical conditions.
In addition to the acute illness being treated, underlying
chronic conditions require ongoing drug therapy. As a result,
these patients are exposed to numerous pharmaceutical
agents, many of which have narrow therapeutic windows
and toxic potential. Comorbid conditions, altered drug
pharmacokinetics, and drug–drug interactions further
enhance the risk for both drug overdosing and underdosing
and adverse medication effects. Underdosing is complicated
by reduced efficacy, whereas overdosing results in various
end-organ toxicities. One such complication is acute kidney
injury (AKI), a relatively common problem in the ICU, which
results from multiple insults. Importantly, potentially
nephrotoxic medications contribute significantly to the
development of AKI. In view of these issues, it is crucial that
clinicians caring for these patients use appropriate drug
dosing based on the knowledge of altered pharmacokinetics,
vigilant monitoring of drug efficacy and toxicity, recognition
of drugs with nephrotoxic potential, and early identification
of drug-induced AKI when it develops.
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Numerous medications are prescribed to seriously ill patients
in the intensive care unit (ICU). Although they provide
significant benefits, adverse events may develop from these
agents, including acute kidney injury (AKI), hepatotoxicity,
neurological dysfunction, cardiopulmonary toxicity, and
other end-organ disturbances. It is therefore incumbent on
all clinicians who provide ICU care to identify these relatively
common complications in patients, with an eye toward
prevention. In addition, practitioners must recognize the
high-risk profile of critical care patients who suffer from
several chronic disease states—this is crucial to under-
standing why end-organ toxicity occurs after exposure to
certain drugs. In this regard, pharmacokinetic changes
accompanying ICU diseases must be factored into drug
dosing to maximize efficacy and minimize toxicity. This
approach can reduce or eliminate potentially preventable
adverse end-organ effects. An example that will be discussed
below in greater detail is AKI.
Several studies have documented that AKI occurs
frequently in the ICU, affecting as many as two-thirds of
patients.1–5 It is often the result of multiple insults and may
be severe enough to require renal replacement therapy (RRT)
in B6% of patients.4,5 As with other acute organ injury
syndromes, AKI has significant consequences, which include
prolonged hospital length of stay, increased hospital-related
morbid events, development of chronic kidney disease
(CKD), and requirement for acute and/or chronic RRT.6
Increased hospital and overall mortality also complicate this
untoward event.6
The major culprits that cause AKI include processes, such
as infections complicated by sepsis, systemic inflammatory
response syndrome, and septic shock, cardiac, hepatic, and
multiorgan dysfunction/failure, as well as volume depletion.
Many of these events prime the kidney for injury by causing
renal hypoperfusion and promoting oxidative stress.7 Im-
portantly, nephrotoxic drugs contribute to AKI in 19–25% of
cases in the ICU.4,8 In fact, 22.2% of the top 100 drugs used
in an adult ICU at a tertiary care center were considered
potentially nephrotoxic.9 Thus, ICU patients are at a
considerable risk of developing AKI, and the critical care
clinician must be familiar with the drugs that commonly
cause nephrotoxicity. This will facilitate appropriate pre-
ventive maneuvers, early identification, and directed disease
management.
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COMMON ICU DISEASE STATES AND COMORBID CONDITIONS
Not surprisingly, patients with significant underlying chronic
disease states are admitted to the ICU with acute, life-
threatening illnesses. The processes noted in Table 1 enhance
the risk for development of one or more of a number of
complications that require admission to and care in the ICU.
The same comorbid conditions that associate with critical
illness also increase the risk for development of both ischemic
and nephrotoxic AKI.
The comorbidities that most notably increase the risk for
drug-induced nephrotoxicity are underlying acute kidney
disease or CKD, sepsis, advanced cirrhosis and liver failure,
acute or chronic left heart failure, pulmonary hypertension
with/without right heart failure, and various types of
malignancies. In addition, a number of major surgical
procedures, such as cardiac surgery, aortic surgery, and
major intra-abdominal surgery enhance nephrotoxic AKI
risk. All of these (Table 2) increase renal injury by one or
more of the following: (1) disturbing renal hemodynamics,
(2) altering drug pharmacokinetics, and/or (3) directly
injuring the renal parenchyma (primarily ischemia). The
common clinical ICU syndromes that increase the risk for
drug-induced AKI are reviewed.
ICU SYNDROMES ASSOCIATED WITH INCREASED AKI RISK
Sepsis
Sepsis, systemic inflammatory response syndrome, and septic
shock are commonly encountered in the ICU. In addition,
sepsis-associated AKI is a frequent complication in patients;
in fact, sepsis is the most common cause of AKI in the ICU,
accounting for up to 50% of cases.5,7,10–12 Renal hemody-
namics are profoundly affected by sepsis, whereby the
systemic vasculature is dilated but vasoconstriction predo-
minates in the kidney. In addition, patients may develop
intravascular volume depletion from the combination of
anorexia, extrarenal fluid losses, and third spacing of fluids
from leaky capillaries. These changes expose the kidney to
reduced perfusion and parenchymal ischemia, even in the
absence of frank hypotension. When shock develops, renal
ischemia is more severe and tubular injury/necrosis occurs.
Finally, intrarenal disseminated intravascular coagulation
may occur with sepsis and further injure the parenchyma.
Therefore, it is not surprising that sepsis is associated with
AKI in the ICU. Importantly, the underlying patient
comorbid conditions (Table 1) magnify the aberrant renal
physiology of sepsis. In addition, these same insults enhance
the risk for certain drugs to cause nephrotoxic AKI, either
alone or in addition to ischemic acute tubular injury. As will
be reviewed later in the discussion of pharmacokinetic
changes in critical care patients, unrecognized renal insuffi-
ciency compounds the problem by the use of excessive drug
dosing for true glomerular filtration rate (GFR).
Heart failure
Advanced cardiac failure commonly requires ICU level of
care, in particular when acute decompensated heart failure
supervenes. Renal function often deteriorates in this setting
because of systemic neurohormonal response, reduced
cardiac output, elevated renal venous pressure, and systemic
hypotension.13–15 In some cases, intra-abdominal compart-
ment syndrome can develop. Reduced renal perfusion is the
end result of these physiological changes, allowing prerenal
AKI or what has recently been coined ‘acute cardiorenal
syndrome’ to develop.14,15 At the other end of the spectrum,
acute tubular injury and frank necrosis may supervene as this
process becomes more severe and prolonged. Drugs with
nephrotoxic potential are more likely to cause AKI in this
milieu, especially medications that further worsen renal
perfusion (such as nonsteroidal anti-inflammatory drugs
(NSAIDs), vasopressors), directly injure renal tubules, or
precipitate within tubular lumens during sluggish urine flow
due to low GFR and obstructing tubular casts. Drug
overdosing associated with impaired drug metabolism and
unrecognized renal impairment further exacerbates AKI risk.
Liver disease
Patients with acute hepatic failure and decompensated
cirrhosis are often admitted to the ICU for evaluation and
therapy. The physiology of liver failure is similar to that of
sepsis with a vasodilated systemic circulation, prominent
Table 1 | Common preexisting comorbidities in ICU patients
Older age (465 years)
Diabetes mellitus
Chronic kidney disease
Cirrhosis and other forms of liver disease
COPD, pulmonary hypertension, and other forms of lung disease
Cardiovascular disease (CAD, CMP, arrhythmias)
Malignancy and its treatment (drugs, HSCT)
Hypertension
Morbid obesity
Abbreviations: CAD, coronary artery disease; CMP, cardiomyopathy; COPD, chronic
obstructive pulmonary disease; HSCT, hematopoietic stem cell transplantation;
ICU, intensive care unit.
Table 2 | Risk factors for drug-induced nephrotoxicity in
the ICU
Chronic risk factors
Older age (465 years)
Chronic kidney disease
Diabetes mellitus
Malignancy
Cardiovascular disease
Liver disease
Chronic pulmonary disease
Hypertension
Peripheral vascular disease
Acute risk factors
Sepsis/infection
Volume depletion (true and effective)
Acute decompensated heart failure
Hypotension
Complex (major) surgery
Trauma
Mechanical ventilation
Abbreviation: ICU, intensive care unit.
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blood pooling in the splanchnic circulation, and renal
arteriolar vasoconstriction.16–19 The presence of tense ascites
can increase renal venous pressure in a manner similar to the
intra-abdominal compartment syndrome. The resulting
reduced renal perfusion pressure and elevated renal venous
pressure increases the risk for AKI, whether due primarily to
hepatorenal syndrome or a superimposed insult, such as
nephrotoxic medications. In this case, NSAIDs, hydroxyethyl
starch, intravenous radiocontrast, and direct tubular toxins
are likely to induce AKI. Disturbed pharmacokinetics, such as
impaired hepatic drug metabolism, have a contributory role
in this group.
Chronic kidney disease
Chronic kidney disease is a common comorbidity in ICU
patients. It is intuitive that disease in the major drug
excretory organ, as manifested by either decreased GFR or
proteinuria, will be associated with increased risk for
nephrotoxic AKI. The reduced volume of functional
parenchyma and smaller number of nephrons increases
nephrotoxic risk. Treatment with excessive doses of poten-
tially nephrotoxic drugs, due to incorrect GFR estimates,
often occurs in the elderly, catabolic states, and with muscle
wasting, which further increases AKI risk. It is not well
appreciated that, in addition to reduced drug excretion, other
pharmacokinetics are also aberrant in CKD. Drug metabo-
lism by the liver (and kidney) is also impaired. For example,
the activity of several cytochrome-P-450 enzymes and drug
transporters (namely P-glycoprotein, organic anion trans-
porter) is reduced in CKD.20–22 As a result, hepatically
metabolized drugs will accumulate and increase tissue
exposure, which may lead to systemic toxicity and AKI, if
the drug has nephrotoxic potential.21
Malignancy
Not uncommonly, patients with various types of cancer are
admitted to the ICU. They frequently have developed
neutropenic sepsis, pulmonary embolism, cardiac or liver
failure, kidney disease, or a complication of bone marrow/
hematopoietic stem cell transplantation.23,24 Although very
often related to the chemotherapeutic regimen, the acute
illness may also be a consequence of the underlying
malignancy. As with the diseases previously discussed,
reduced renal perfusion, ischemic tubular injury, and direct
parenchymal injury from tumor invasion or tumor lysis
increase the risk for development of AKI from various
medications. Radiocontrast, NSAIDs, and numerous che-
motherapeutic agents are also included.
PHARMACOKINETIC CHANGES IN ICU PATIENTS
Outside innate drug toxicity and the disease states discussed
above, one of the major factors leading to drug-induced
systemic toxicity is disturbed medication pharmacokinetics
in critically ill patients (Table 3). All phases of drug
pharmacokinetics are disturbed in ICU patients, including
absorption, distribution, metabolism, and clearance.25 These
changes are often the result of organ dysfunction, particularly
in the kidneys and liver, the acute-phase response of the
underlying critical illness, multiple drug interactions, and
therapeutic interventions, including intravenous fluids,
diagnostic procedures, and various medications.25–27 Indivi-
dual differences in the pharmacogenetics of drug transport
systems and metabolizing enzymes may be exacerbated in
this setting, further increasing the risk of toxicity.
Bioavailability
Although drug bioavailability is less of an issue with
intravenously administered medications, oral, subcutaneous,
and intramuscular drugs often have altered bioavailability in
ICU patients. Reduced absorption of enteral drugs occurs
because of a number of factors, including increased gastric
pH (alters the drug-ionized state), bowel dysmotility,
formation of insoluble drug complexes in the intestines,
nutrient–drug interactions, and bowel edema.25 Acute
decompensated heart failure and cirrhosis will reduce oral
bioavailability due to bowel edema and impaired intestinal
perfusion. A less-appreciated cause of reduced absorption is
intestinal atrophy with associated decreased surface area and
cellular enzyme activity, which can occur as a result of as little
as 3 days of reduced enteral feeding.25,28 On the basis of these
data, it is prudent to dose medications intravenously and to
initiate enteral feeds early to avoid gut atrophy. Less
commonly, reduced intestinal/hepatic metabolism of enteral
drugs actually increases their bioavailability.28
Distribution
Drug distribution is significantly altered in ICU patients for
various reasons. This is due primarily to changes in the
factors that determine distribution: blood delivery, tissue
permeability, microenvironment pH, and drug characteris-
tics, such as lipid solubility, pKa, and protein binding.25 The
initial concentration of a drug after intravenous administra-
tion is determined by dose and volume of distribution (Vd),
Table 3 | Pharmacokinetic differences in ICU patients
Altered oral drug bioavailability (decreased4increased)
Intestinal atrophy, dysmotility, and reduced transport function
Reduced intestinal and hepatic metabolism
Altered volume of distribution (increased or decreased)
Increased or decreased extracellular fluid space
Decreased protein concentration or binding
Altered tissue permeability
Microenvironment pH disturbances
Altered drug metabolism/biotransformation (decreased4increased)
Altered CYP-450 drug metabolism
Altered drug cellular transport
Altered renal drug clearance (decreased4increased)
Reduced GFR
Reduced proximal tubular drug secretion (drug competition,
endogenous organic anions/cations, tubular injury)
Abbreviations: CYP, cytochrome P; GFR, glomerular filtration rate; ICU, intensive
care unit.
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a hypothetical space representing total body drug concen-
tration divided by plasma blood concentration. In critical
illness, Vd may be increased or decreased depending on the
level of total body water, level of renal function, and changes
in protein concentration and binding affinity.25–27 Increased
drug Vd often develops from early goal-directed therapy for
sepsis, edematous states, such as cirrhosis and acute hepatic
failure, nephrotic syndrome, right and left heart failure, and
many illnesses associated with shock requiring aggressive
volume repletion to maximize end-organ perfusion. Efficacy
can suffer if drug dosing is not adjusted to these changes.
Reduced Vd may be seen with older age and volume depletion
from vomiting, diarrhea, blood loss, and diuretics. AKI and
CKD may also reduce the Vd of certain drugs by altering
tissue binding.20,25 Drug therapy that does not account for
this will lead to excessive dosing and end-organ toxicity.
Metabolism
Drug metabolism is disturbed by many of the critical illness
states.25–27 The two major metabolic pathways for drugs are
categorized as phase I and II. Although the liver is the major
organ involved in these pathways, the intestines, kidneys, and
other organs also participate to a lesser degree. Phase I entails
oxidation, reduction, and hydrolysis of certain drugs. Hepatic
metabolism is influenced by the level of blood flow,
hepatocyte enzyme activity, and protein binding. Vigorous
hepatic blood flow allows drugs with high extraction ratios to
be rapidly cleared; these drugs accumulate when perfusion is
reduced by hypotension/shock, vasoconstrictor drugs, venti-
lation with positive end expiratory pressure, and impaired
cardiac output.25–27 For drugs with low extraction ratios, the
enzyme function is most important and is performed
primarily by the cytochrome P-450 system. An essential
component of enzyme function is tissue transporter activity,
which participates in uptake and removal of drugs from the
liver and other metabolizing organs.25–28 Drug transporters
such as p-glycoprotein and organic anion transporter may be
affected by critical illness states, such as inflammation, sepsis,
CKD/AKI, acute or chronic liver disease, hypotension, burns,
and trauma.25–28 In general, these processes have variable
effects on transporter activity, while predominantly reducing
cytochrome P-450 enzyme activity. Thus, the metabolism of
drugs in ICU patients is clearly altered and likely contributes
to efficacy and toxicity issues. AKI may result when
potentially nephrotoxic drugs and/or their active metabolites
accumulate.29
Excretion
Drugs are eliminated from the body by both renal and
nonrenal pathways. Hepatic clearance is considerable for
lipophilic drugs, whereas hydrophilic drug excretion is largely
a function of renal clearance. Currently used markers of
kidney function, such as serum creatinine concentration, are
suboptimal, especially in the ICU setting. Resuscitation with
large volumes of crystalloid will dilute serum creatinine
concentration masking the presence of AKI or misinforming
about the stage of CKD. Creatinine production is also
reduced in sepsis, further limiting its potential as a marker of
kidney injury.30 Thus, abrupt decreases in GFR initially may
be accompanied by little or no change in the serum
creatinine. As a result, parent drugs and active metabolites
from liver metabolism that are excreted by the kidneys,
accumulate and can cause toxicity. In addition, drug
clearance is affected by the etiology of critical illness. As
compared with normal subjects, burn patients more often
have increased clearance because of younger age, aggressive
fluid resuscitation, and hypermetabolic state.25 In contrast,
studies on patients in medical and surgical ICUs demonstrate
no change or reduced drug clearance as compared with
normal subjects.25 However, these are only generalizations,
and patients with any of the noted illnesses can have
increased, unchanged, or decreased drug clearance, empha-
sizing the need for individualized dosing. Thus, ICU patients
are at risk for underdosing with loss of efficacy and adverse
toxic events from drug overdosing, especially when GFR is
overestimated by an inaccurate parameter, such as serum
creatinine.
With severe AKI in the ICU, some form of RRT is often
required. Acute intermittent hemodialysis and various forms
of continuous RRT are used to provide clearance, metabolic
control, and fluid balance. Drug clearances and changes in
pharmacokinetics must be considered with addition of this
therapy.31 Not only must drug dosing take into account RRT-
associated clearances but also dialysis-induced changes in Vd
and drug distribution, as well as the associated improvement
in hepatic and other organ drug metabolism. The latter point
is important and not commonly appreciated with dialytic
therapy of the uremic patient. In addition, one must
recognize that extracorporeal drug clearances are different
with chronic RRT (CRRT) and intermittent hemodialysis. As
will be discussed later, continuous convective clearance
requires dosing regimens that are distinct from intermittent
diffusion-based hemodialysis.
Finally, pharmacokinetic changes that occur with critical
illness are by no means static but rather represent a dynamic
process. Many change as the clinical status of the patient
changes. For example, eradication of infection, recovery
of end-organ dysfunction, improvement in intravascular
volume status, and enhanced nutritional status are but a few
of the changes that occur in this unique subset of patients.
Alternatively, patients may deteriorate and develop worsening
anasarca, hypotension, new end-organ failure, and a
progressive decline in clinical status. As such, these changes
must be kept in mind when prescribing medications, with
vigilant monitoring as integral to appropriate therapy.
DRUG DOSE ADJUSTMENT IN ICU PATIENTS
On the basis of the altered drug pharmacology of ICU
patients, prescription of drugs to these patients should be
carefully contemplated. Understanding the general pharma-
cological principles in ICU patients combined with knowl-
edge of individual patient pharmacokinetic differences will
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allow more informed dosing strategies. This therapeutic
approach will facilitate maximal efficacy and minimal toxicity
by limiting underdosing and overdosing. To best achieve this,
it is critical to work collaboratively with the clinical
pharmacist in the ICU. A simple approach is to guide drug
dosing by applying the pharmacokinetic principles that affect
drug loading dose and maintenance dose (Figure 1). Loading
dose takes into account primarily the Vd, drug solubility
(lipid vs water), protein binding, and tissue permeability.32,33
A formula that can be used to modify drug dose based
on Vd is loading dose¼ standard loading dose (patient’s
Vd/normal Vd). In contrast, maintenance dose primarily
takes into account the status of hepatic metabolism and
more importantly, renal excretion.32,33 To guide maintenance
dosing, formulas based primarily on kidney function can
modify the dose or dosing interval: maintenance dose¼
standard dose (patient’s CrCl/normal CrCl), or mainte-
nance dosing interval¼ standard dosing interval (normal
CrCl/patient’s CrCl), or a combination of the two approaches
(reduced dose and increased interval). The presence of
RRT will require an adjustment in dosing to account for
drugs that are efficiently removed by this modality and the
improvement in hepatic metabolism that accompanies
correction of uremia.31 Knowledge of the underlying drug
characteristics and the effect of both acute illness and chronic
comorbid conditions on pharmacokinetic principles, along
with vigilant monitoring will allow a reasonably safe dosing
regimen in most ICU patients. The influence of critical illness
on drug pharmacokinetics and dosing is evident in the
following scenario. A patient with septic shock receives early
goal-directed therapy with 6 l of saline for hypotension. The
patient is edematous and oliguric with increasing serum
creatinine. Intravenous antibiotics must be administered to
treat infection. An informed approach to drug dosing is as
follows: the loading dose of a water-soluble drug must be
increased because of the larger Vd, whereas the maintenance
dose must be reduced to account for reduced renal drug
excretion, with some contribution from impaired hepatic
metabolism.
As extracorporeal drug clearances vary based on the
modality used in ICU patients, dosing regimens must be
appropriately adjusted to the dialytic therapy. With CRRT,
the convective mode of clearance and the continuous nature
of the procedure make the impact of drug size, Vd, and
drug–membrane interactions less important as compared
with intermittent hemodialysis.31 Maintenance drug dosing
in patients on CRRT is best estimated using total creatinine
clearance (patientþ therapy). With high-volume CRRT
(425ml/kg per h), most drugs should be dosed based on a
creatinine clearance between 25 and 50ml/min.31 In contrast,
maintenance drug dosing with intermittent hemodialysis
should be guided by published dosing recommendations
based on creatinine clearance o10ml/min with postdialysis
administration. Thus, as a patient transitions from CRRT to
intermittent hemodialysis (or vice versa), drug dosing must
be adjusted accordingly.
 Drug Vd 
• Water vs lipid soluble
• Protein binding
• Tissue permeability
• ECF volume
• Blood delivery
• Microenvironment pH   
Maintenance
dose
Vd 
drug dose#
Vd 
 drug dose#
1) 
2) 
drug dose*
or
dosing interval** 
or
combine both 
drug dose*
or
dosing interval** 
or
combine both 
1) 
2) 
3) 3) 
Readjust drug loading and maintenance dose based on changes in clinical status
Metabolism
 drug dose 
Metabolism
 drug dose 
Excretion 
• Primarily kidney
and hepatic  
Adjust drug dosing with RRT 
Metabolism 
• Primarily hepatic
Loading
dose
Excretion Excretion
Figure 1 |A simplified approach to loading and maintenance drug dosing in the ICU. For loading dose, estimate the drug Vd (taking
in account drug and patient characteristics) and dose accordingly using the simple formula. For maintenance dose, estimate the renal
clearance (CrCl) for the drug and adjust the dose and/or dosing interval accordingly. #Loading dose¼ standard dose (patient’s Vd/normal
Vd). *Maintenance dose¼ standard dose (patient’s CrCl/normal CrCl). **Maintenance dosing interval¼ standard interval (normal
CrCl/patient’s CrCl). CrCl, creatinine clearance; ECF, extracellular fluid; ICU, intensive care unit; RRT, renal replacement therapy; Vd, volume
of distribution.
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NEPHROTOXIC COMPLICATIONS OF ICU DRUG THERAPY
Many drugs are associated with nephrotoxicity in the
ICU and they have been reviewed in detail in previous
reviews.34–36 Innate drug toxicity, aberrant renal hemo-
dynamics, underlying kidney disease, and altered drug
pharmacokinetics all have a role in their enhanced nephro-
toxicity. Broad categories of drug nephrotoxicity in the
ICU will be briefly touched on; Table 4 lists some common
examples.
Hemodynamic AKI
Hemodynamic or prerenal AKI is common in the ICU.
Patients have disturbed systemic and renal hemodynamics,
capillary leak syndrome, and extensive fluid losses. In
addition, underlying CKD and hypertensive arterionephro-
sclerosis are common. These factors predispose patients to
hemodynamic AKI when therapy with NSAIDs, renin–angio-
tensin–aldosterone system blockers, high-dose systemic
vasoconstrictors, or calcineurin inhibitors is undertaken.37
Each acts by different mechanisms to reduce GFR. NSAIDs
reduce vasodilatory prostaglandins, renin–angiotensin–aldo-
sterone system blockers inhibit angiotensin-II effects on the
efferent arteriole, and vasoconstrictors and calcineurin
inhibitors increase afferent arteriolar tone.38 In general, the
reduction in GFR is rapidly reversible.
Acute tubular injury
Acute kidney injury from acute tubular injury/necrosis
occurs frequently in ICU patients. The same risk factors that
predispose to prerenal AKI also increase the risk for tubular
injury. Direct tubular toxicity is well known with drugs
frequently used in the ICU—aminoglycosides, anti-fungal
agents, and radiocontrast are examples. Crystal-induced
tubular injury and luminal obstruction is more likely to
occur in these patients when intravenous drugs such as
acyclovir, sulfa-based medications, ciprofloxacin, and meth-
otrexate are administered.39 An interesting and under-
recognized cause of acute tubular injury is the entity
known as ‘osmotic nephropathy.’ Intravenous immunoglo-
bulin using a sucrose stabilizer causes AKI, with the renal
lesion characterized by swollen proximal tubular cells filled
with abundant lysosomal vacuoles.39 It has recently been
recognized that certain forms of hydroxyethyl starch increase
AKI in sepsis and cardiac surgery when compared with other
volume expanders.40 The kidney lesion observed is identical
to the one noted with sucrose.39
Acute interstitial nephritis
Acute interstitial nephritis (AIN) is without doubt the most
difficult cause of AKI to firmly establish in the ICU. The
absence of clinical or laboratory findings to suggest an
allergic drug reaction is a major reason, while exposure to
numerous drugs makes it nearly impossible to identify the
likely causative agent. As AIN is an idiosyncratic drug
reaction, risk is based primarily on the sheer number of drugs
this group is exposed to in the ICU setting. Nonetheless, as
drug-induced AIN has been described to cause AKI in 3–10%
(as high as 27% in selected patients), one must remain
vigilant to the possibility.41 Although any medication can
cause AIN, certain drugs (Table 4) are more likely and they
are broadly classified as antimicrobials, anti-ulcer agents,
anti-convulsants, diuretics, and a host for other medica-
tions.41 To make the diagnosis, a high index of suspicion for
drug-induced AIN as the cause of AKI and a confirmatory
kidney biopsy are required.
CONCLUSIONS
Drug use is extensive in the ICU, and although life saving, is
fraught with complications and various forms of toxicity.
One notable complication is drug nephrotoxicity, which
develops more readily in ICU patients because of the
underlying comorbid conditions that enhance risk. Further-
more, acute ICU illnesses are associated with hemodynamic
changes that reduce renal perfusion, complications that
directly injure the renal parenchyma, and altered drug
pharmacokinetics—all of these increase the risk for drug-
induced AKI and other drug-related complications. Nephrol-
ogists and intensivists working in the ICU can potentially
reduce drug toxicity by recognizing the high-risk profile of
these patients. Pharmacokinetic changes accompanying ICU
diseases, individualized to each patient, must be factored into
drug dosing to maximize efficacy and minimize toxicity.
Close collaboration with a clinical pharmacist and applying
fundamental pharmacokinetic principles to drug adminis-
tration is required. This approach can go a long way in
eliminating or reducing drug nephrotoxicity and other
adverse end-organ drug effects.
Table 4 | Common forms of drug-induced AKI in the ICU
Hemodynamic AKI
Nonsteroidal anti-inflammatory drugs (NSAIDs)
RAAS inhibitors
Calcineurin inhibitors (cyclosporine, tacrolimus)
Vasopressors
Acute tubular necrosis
Radiocontrast
Nephrotoxic antimicrobials
Osmotic nephropathy
Hydroxyethyl starch (HES)
Intravenous immunoglobulin (IVIG containing sucrose)
Crystal nephropathy
Highly active anti-retroviral therapy (HAART)
Acyclovir
Ciprofloxacin
Sodium phosphate purgatives
Acute interstitial nephritis
Antibiotics (b-lactams, sulfa-based, quinolones)
Proton pump inhibitors, H2 antagonists
Anti-convulsants
Abbreviations: AKI, acute kidney injury; H2, histamine-2; ICU, intensive care unit;
NSAIDs, nonsteroidal anti-inflammatory drugs; RAAS, rennin–angiotensin–aldoster-
one system.
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